Proven Health brand history email designs you can use

This email aims to announce Basilea’s strategic partnership with INCATE to position the company as a leader in antifungal innovation and to build credibility with stakeholders by aligning with a respected European research incubator focused on early-stage antimicrobial therapies.

By framing the partnership as a milestone for both Basilea and INCATE, the email elevates the announcement beyond a simple collaboration into a strategic industry signal that reinforces credibility and forward-looking leadership in antifungal therapeutics.

Including direct quotes from both Basilea’s Chief Scientific Officer and INCATE’s Vice President adds authoritative voice and emotional weight, making the partnership feel like a shared mission rather than a transactional alliance, which deepens stakeholder trust.

Add a visual timeline or infographic showing how Basilea’s R&D pipeline connects with INCATE’s incubation model to make the partnership’s value proposition more tangible and easier to digest for non-scientific stakeholders. • Reposition the CTA ‘Download the press release (PDF)’ higher in the email, ideally beneath the hero section, to reduce friction for readers who want immediate access to the full announcement without scrolling through dense text.

To announce and highlight the strong sales performance of Cresemba® in Asia Pacific and China, which triggered a USD 5 million milestone payment to Basilea, reinforcing investor and stakeholder confidence in the drug’s market value and commercial success.

The email strategically ties commercial success directly to financial reward, a USD 5 million milestone payment, making the achievement tangible and reinforcing investor confidence through clear cause-and-effect storytelling.

By anchoring the announcement in specific regional performance (Asia Pacific and China) and citing year-over-year growth (27%), the message builds credibility through data while subtly signaling global scalability and market demand for the antifungal therapy.

Add a visual element such as a small bar chart or growth icon next to the 27% YoY sales increase to make the performance metric more immediately digestible and visually compelling for skimming readers. • Include a brief, bolded summary sentence at the top, e.g., 'Cresemba® sales in Asia Pacific & China exceeded targets, triggering $5M milestone payment', to immediately convey the core news before diving into details.

This email aims to inform healthcare professionals and stakeholders in the EU about the CHMP’s positive opinion recommending finerenone for treating heart failure patients with LVEF ≥40%, while reinforcing Bayer’s leadership in cardiovascular innovation and building confidence in the drug’s clinical value.

The email strategically anchors its message in regulatory validation by leading with the CHMP’s positive opinion, immediately establishing credibility and clinical relevance for a specialized audience of medical professionals and decision-makers.

It effectively contextualizes the drug’s significance by pairing trial data with real-world epidemiology, highlighting that over 15 million Europeans suffer from HF with LVEF ≥40%, making the therapeutic gap tangible and urgent for stakeholders.

Add a visual timeline or infographic summarizing the FINEARTS-HF trial design and key endpoints to improve comprehension for time-constrained clinicians who may skim the email. • Include a direct, action-oriented CTA button (e.g., 'Download Full Trial Data' or 'Request Clinical Materials') alongside the link to encourage deeper engagement beyond passive reading.

This email aims to position Bayer as a global sustainability leader by highlighting its active participation in COP30, its partnerships for rainforest conservation, and its progress toward renewable energy and climate-smart agriculture. It seeks to build trust with stakeholders by showcasing measurable environmental commitments and innovations.

Bayer masterfully ties its corporate presence at COP30 to tangible environmental outcomes, like restoring a historic building in Belém and launching ‘Casa Bayer’, making abstract climate commitments feel grounded, local, and human-centered for global audiences.

The email strategically weaves together multiple sustainability threads, carbon farming, aviation fuel partnerships, and renewable energy targets, into a cohesive narrative that positions Bayer not just as a participant, but as a catalyst for systemic change across industries and geographies.

Add a clear primary CTA button above the fold, such as 'Explore Bayer’s Climate Solutions' or 'See Our COP30 Impact', to guide readers toward deeper engagement instead of relying solely on passive footer links. • Include a visual timeline or infographic summarizing Bayer’s key milestones (e.g., 3 million hectares, 100% renewable energy by 2026) to make complex data more digestible and reinforce the brand’s progress at a glance.

This email aims to celebrate Cool Crutches’ 20-year milestone by honoring the community that transformed mobility aids from clinical tools into confident, stylish statements, while reinforcing brand loyalty and inspiring continued engagement through storytelling and product discovery.

The email masterfully reframes disability aids as symbols of empowerment and style, using personal narrative and community impact to emotionally connect with readers while subtly reinforcing product desirability through real-life usage and design recognition.

By spotlighting collaborations with organizations like MS Society and the V&A, the brand elevates its mission beyond commerce into cultural relevance, making customers feel they’re part of a movement, not just buyers, deepening emotional investment and brand advocacy.

Add a subtle countdown or limited-time offer tied to the 20th anniversary in the hero or CTA section to create urgency and incentivize immediate engagement, leveraging the milestone’s emotional weight to drive conversions. • Include a short video or animated carousel in the 'Our Cool Crutches Community' section to bring user stories to life visually, increasing emotional resonance and time-on-page while reinforcing authenticity through real customer voices.

To inform investors and stakeholders about Basilea’s strengthened clinical portfolio, recent milestones in drug development, and commercial performance in 2025, while reinforcing confidence in its strategic direction and growth outlook for 2026.

Basilea effectively anchors its investor update in tangible commercial milestones, like Cresemba’s 10th anniversary and 27% sales growth, making abstract R&D progress feel concrete and results-driven for stakeholders.

The email strategically ties early-stage innovation to real-world impact by highlighting partnerships with BARDA and AI-driven collaborations, which positions Basilea not just as a drug developer but as a forward-thinking ecosystem player solving global health challenges.

Add a visual timeline or milestone graphic near the top to summarize key 2025 achievements and 2026 goals, this would improve scannability and help investors quickly grasp progress without reading dense paragraphs. • Include a short video or audio clip from the CEO summarizing the outlook, this would humanize the message, increase engagement, and reinforce leadership confidence beyond the written quote.

This email aims to announce Bayer’s strategic market entry into the strawberry sector with the launch of Baya Solara, positioning it as a high-yield, disease-resistant variety that solves key grower challenges while reinforcing Bayer’s innovation leadership in crop science.

Bayer brilliantly frames the new strawberry variety not just as a product, but as a strategic solution to industry-wide pain points, highlighting yield, disease resistance, and labor efficiency to immediately resonate with commercial growers’ operational realities.

The email leverages executive quotes to humanize the innovation, giving credibility through leadership voices that speak directly to both grower needs and consumer benefits, which builds trust and positions the launch as a market-transforming milestone rather than just a product update.

Add a visual comparison chart or infographic showing Baya Solara’s performance metrics (yield, disease resistance, shelf life) against industry benchmarks to make technical advantages instantly digestible for time-pressed growers. • Include a clear, secondary CTA such as 'Request a Sample' or 'Schedule a Grower Consultation' to convert reader interest into actionable next steps, especially since the primary CTA only links to a press release without a direct path to engagement.

This email aims to inform healthcare professionals and stakeholders about the European Union’s approval of Eylea™ 8 mg for a third retinal indication, specifically for macular edema following retinal vein occlusion, while reinforcing Bayer’s leadership in ophthalmology innovation and clinical efficacy.

The email strategically anchors its message in clinical trial data, specifically the QUASAR study, to build credibility and demonstrate real-world patient benefits, such as extended dosing intervals and maintained visual acuity, which directly address treatment burden concerns.

By including direct quotes from both a leading ophthalmologist and a Bayer executive, the email blends scientific authority with corporate vision, creating a dual-layered persuasive appeal that resonates with both clinical and strategic decision-makers.

Add a visual timeline or infographic summarizing the QUASAR trial results, especially the 60% of patients achieving 4+ month dosing intervals, to make complex data more digestible and emotionally resonant for time-constrained clinicians. • Include a clear, visually distinct CTA button (e.g., 'Download Full Trial Data') near the top of the email to reduce friction for readers seeking deeper clinical evidence, rather than relying solely on a text-based link buried in the footer.

This email aims to inform stakeholders, investors, and the medical community about Bayer’s regulatory milestone: receiving Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for HER2-mutant NSCLC, reinforcing Bayer’s innovation leadership in oncology.

The email strategically anchors its message in regulatory validation, highlighting Breakthrough Therapy Designation in both the U.S. and China, to immediately signal global credibility and accelerate stakeholder confidence in the drug’s clinical potential.

By weaving in clinical trial data, mechanism of action, and patient need context, the email transforms a regulatory update into a compelling narrative of scientific progress, making complex oncology developments accessible and emotionally resonant for non-specialist readers.

Add a visual timeline or infographic in the Education Section to illustrate the drug’s development journey, from discovery to Breakthrough Designation, to help readers quickly grasp the significance of this milestone without wading through dense text. • Reposition the primary CTA higher in the email, perhaps as a clickable button beneath the headline, to reduce friction for readers seeking immediate access to clinical data or press materials, especially since the current link is buried in the footer.

This email aims to position Cool Crutches as a superior, lifestyle-oriented alternative to hospital-issued walking aids by highlighting comfort, design, and long-term usability, ultimately driving first-time customers to shop the collection with confidence and urgency.

Cool Crutches brilliantly reframes the walking aid from a medical necessity to a lifestyle upgrade by contrasting hospital crutches’ limitations with their own comfort, style, and ergonomic benefits, making the product emotionally resonant, not just functional.

The email leverages social proof with precision by highlighting a 5-star rating from over 45,000 customers, which builds instant credibility and reduces purchase hesitation for first-time buyers who may be skeptical about non-hospital brands.

Add a visual comparison slider or side-by-side image showing hospital crutches vs. Cool Crutches to make the ‘upgrade’ claim instantly tangible, currently, the contrast is only verbal, which weakens emotional impact for visual learners. • Reposition the CTA ‘Shop the collection >’ higher in the email, ideally after the first benefit bullet, to capture attention before the reader scrolls past, the current placement risks losing momentum after the long feature list.